Compare Amgen, Inc. (AMGN) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Plug Power Inc — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Plug Power Inc trades at $2.21 (market cap $3.11B). The key difference: Amgen, Inc. is far larger — about 63.1× Plug Power Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals.
| AMGN | PLUG | |
|---|---|---|
Market Cap | $196.12B | $3.11B |
Sector | Health | Industrials |
52-Week High | $388.16 | $4.14 |
52-Week Low | $271.18 | $1.40 |
Enterprise Value | $241.41B | $3.90B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PLUG trades at $2.23, down 6.3% on the day, with a bearish technical signal and negative cash flows. The company reported a net loss of $1.63 billion in 2025 despite revenue of $710 million, with gross profit margin at -25.66%. Recent news includes a 50MW electrolyzer order for the Hunter Valley Hydrogen Hub in Australia, but the stock faces pressure from analyst target cuts and high short interest of 27.4%.
Outlook remains challenged by persistent losses and cash burn, though analyst consensus suggests 31% upside to the $2.92 target. Key risks include delayed profitability targets beyond 2028 and reliance on financing amid negative operating cash flow. The stock's viability hinges on successful project execution and hydrogen market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
